ce is being deposited with the US Postal Service with sufficient postage as First Class Mail in Stop Amendment, Commissioner for Patents, P.O box 1450, Alexandria, VA 22313-1450, on the an envelope addressed as a little and date shown below. Date: November 16, 2006

> **PATENT** Docket No. GC800-2-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| In re Application of Jones et al. |)) Group Art Unit: |
|---|-----------------------------|
| Serial No.: 10/555,587 |) Examiner: Unassigned |
| Filed: May 12, 2004 |) |
| For: Novel Lipolytic Enzyme ELIP |) |
| Supplemental Infor | mation Disclosure Statement |
| Mail Stop Amendment Commissioner for Patents | |

P.O Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449 and attached thereto) of which they are aware, that they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

| §1.97(a). |
|--|
| (b) is filed within three months after the filing date of the application or within three months after the date of entry into the national stage of a PCT application as set forth in 37 CFR §1.491. |
| (c) $igotimes$ as far as is known to the undersigned, is filed before the mailing date of a first Office Action on the merits. |

(d) is filed after the first Office Action and more than three months after the

(a) accompanies the new patent application submitted herewith. 37 CFR

| | as is kr rejection either the specified Deposition | tion filing date or PCT national stage date of entry filing but, as far nown to the undersigned, prior to the mailing date of either a final on or a notice of allowance, whichever occurs first, and is accompanied by the fee (\$180.00) set forth in 37 CFR §1.17(p) or a certification as ed in 37 CFR §1.97(e), as checked below. Authorization to charge to the Account No. 07-1048 in the amount of \$180.00 to cover the cost of this action Disclosure Statement is provided in the Transmittal Letter submitted the in duplicate. |
|------------------|--|---|
| | allowar Transn No. 07- as spe- conside | is filed after the mailing date of either a final rejection or a notice of nce, whichever occurred first, and is accompanied by authorization (in the nittal Letter submitted herewith in duplicate) to charge Deposit Account 1048 the fee (\$180.00) set forth in 37 CFR §1.17(I)(1) and a certification cified in 37 CFR §1.97(e), as checked below. This document is to be sered as a petition requesting consideration of the Supplemental ation Disclosure Statement. |
| [If either of be | oxes (d | or (e) is checked above, the following "certification" under 37 CFR |
| §1.97(e) may | need to | be completed.] The undersigned certifies that: |
| | counte | Each item of information contained in the Information Disclosure ent was cited in a communication mailed from a foreign patent office in a rpart foreign application not more than three months prior to the filing of ormation Disclosure Statement. |
| | foreign reason | No item of information contained in this Information Disclosure Statement ed in a communication mailed from a foreign patent office in a counterpart application or, to the knowledge of the undersigned after making able inquiry, was known to any individual designated in 37 CFR §1.56(c) nan three months prior to the filing of this Information Disclosure tent. |
| A copy of the i | tems o | n Form PTO-1449 is supplied: PCT International Search Report for PCT/ |
| US200401468 | 5, filed | May 12, 2004 with attached patents and publications. |
| ☐ eac | h ⊠r | one only those listed below: |
| A concise exp | lanation | of relevance of the items listed on PTO-1449 is: |
| | \boxtimes | not given |
| | | given for each listed item |
| | | given for only non-English language listed item(s) |
| | _ | in the form of an English language copy of a Search Report from a patent office, issued in a counterpart application, which refers to the portions of the references. |

Attorney Docket No. GC800-2-US Page 3

The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Janet Kaiser Castaneda Registration No. 33,228

Date: November 16, 2006

Genencor International, Inc. 925 Page Mill Road Palo Alto, CA 94304-1013

Tel: 650 846-7615 Fax: 650 845-6504

INFORMATION DISCLOSURE CITATION Attorney Docket No.: GC800-2-US Serial No.: 10/555,587 Applicant: Jones et al. Filing Date: May 12, 2004 Group: Date of this Submission: November 16, 2006 Page of 1 **US PATENT DOCUMENTS** Examiner's **Document** Sub-**Filing** Initial Number Date Class Class Name **Date** FOREIGN PATENT DOCUMENTS **Examiner's Translation Document** Sub-Initials Number Yes/No Date Class Class Country WO 93/09219 05/13/93 **PCT** WO 04/101763 11/25/06 **PCT** 11/25/06 WO 04/101759 PCT **OTHER DOCUMENTS** Examiner's Author, Title, Date, Pertinent Pages, etc. Initials Database Embl - 22 March 2001 - "NF082F11PL1F1093Phosphate starved leaf Medicago truncatula cDNA clone NF082F11PL5", mRNA sequence. »Database accession no. BG45687 Abstract Jaeger et al., "Bacterial biocatalysts: molecular biology, three-dimensional strucrtures, and biotechnological applications of lipases." Annual Review of Microbiology, (1999) V. 53, pp.315-351 Copy of the Supplementary European Search Report Examiner **Date Considered** Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not

GC IDS-1449

PTO-1449

considered. Include copy of this form with next communication to applicant.